← Browse by Condition
Medical Condition
recurrent laryngeal squamous cell carcinoma
Total Trials
2
Recruiting Now
2
Trial Phases
Phase 2
NCT06636734 Phase 2
Recruiting
Lovastatin and Pembrolizumab for the Treatment of Patients With Recurrent or Metastatic Head and Neck Cancer, LAPP Trial
Enrollment
28 pts
Location
United States
Sponsor
Emory University
NCT06980038 Phase 2
Recruiting
Testing Whether Cemiplimab (REGN2810) Plus CDX-1140 Given Prior to Surgery Are Better Than Cemiplimab (REGN2810) Alone in Patients With Stage III-IV Head and Neck Cancer
Enrollment
44 pts
Location
United States
Sponsor
National Cancer Institute (NCI...